Composition for treating prostate cancer (PCa)

Patent metadata

Field	Value
Publication number	US-12048738-B2
Application number	US-201916548112-A
Country	US
Kind code	B2
Filing date	Aug 22, 2019
Priority date	Oct 9, 2007
Publication date	Jul 30, 2024
Grant date	Jul 30, 2024

Abstract

The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate), The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.

First claim

The invention claimed is:

1. An isolated mRNA comprising a Prostate-Specific Antigen (PSA) polypeptide coding sequence at least 90% identical to an mRNA encoded by the sequence of SEQ ID NO: 3, wherein the polypeptide coding sequence encodes the PSA polypeptide sequence encoded by the sequence of SEQ ID NO: 3 or an antigenic fragment of the PSA polypeptide encoded by SEQ ID NO: 3.

2. The isolated mRNA of claim 1 , comprising a Prostate-Specific Antigen (PSA) polypeptide coding sequence at least 90% identical to an mRNA encoded by the sequence of SEQ ID NO: 3, wherein the polypeptide coding sequence encodes an antigenic fragment of the PSA polypeptide encoded by SEQ ID NO: 3.

3. The isolated mRNA of claim 1 , comprising a Prostate-Specific Antigen (PSA) polypeptide coding sequence at least 90% identical to an mRNA encoded by the sequence of SEQ ID NO: 3, wherein the polypeptide coding sequence encodes the PSA polypeptide sequence encoded by the sequence of SEQ ID NO: 3.

4. The isolated mRNA of claim 1 , wherein the polypeptide coding sequence is at least 95% identical to an mRNA encoded by the sequence of SEQ ID NO: 3.

5. The isolated mRNA of claim 4 , wherein the polypeptide coding sequence is at least 97% identical to an mRNA encoded by the sequence of SEQ ID NO: 3.

6. The isolated mRNA of claim 5 , wherein the polypeptide coding sequence is 100% identical to an mRNA encoded by the sequence of SEQ ID NO: 3.

7. The isolated mRNA of claim 1 , wherein the mRNA is complexed with at least one cationic or polycationic compound.

8. The isolated mRNA of claim 7 , wherein the cationic or polycationic compound is chosen from the group consisting of cationic lipids, cationic polysaccharides, cationic or polycationic peptides or proteins, and polycationic polymers.

9. The isolated mRNA of claim 8 , wherein the mRNA is complexed with protamine.

10. The isolated mRNA of claim 1 , wherein the mRNA comprises a 5′ cap structure.

11. The isolated mRNA of claim 1 , wherein the mRNA additionally comprises a poly-A tail of 10 to 200 adenosine nucleotides.

12. The isolated mRNA of claim 1 , wherein the mRNA additionally comprises a poly-C tail of 10 to 200 cytosine nucleotides.

13. The isolated mRNA of claim 1 , wherein the mRNA further comprises a 5′ and/or a 3′ untranslated region (UTR).

14. The isolated mRNA of claim 1 , wherein the mRNA comprises at least one nucleotide that is substituted with a nucleotide analog chosen from the group consisting of: 5-methylcytidine 5′ monophosphate and pseudouridine.

15. A method of treating a subject having prostate cancer comprising administering an effective amount an mRNA according to claim 1 to the subject.

16. An immunostimulatory composition comprising:
i) at least a first RNA comprising a coding region encoding prostate specific antigen (PSA), wherein the RNA is an mRNA comprising a Prostate-Specific Antigen (PSA) polypeptide coding sequence at least 90% identical to an RNA encoded by the sequence of SEQ ID NO: 3, wherein the polypeptide coding sequence encodes the PSA polypeptide sequence encoded by the sequence of SEQ ID NO: 3; and
ii) at least a second RNA comprising a coding region encoding a polypeptide selected from the group consisting of Prostate-Specific Membrane Antigen (PSMA), Prostate Stem Cell Antigen (PSCA), and Six Transmembrane Epithelial Antigen of the Prostate (STEAP).

17. A method of stimulating an anti-tumor immune response in a subject comprising administering an effective amount of an immunostimulatory composition of claim 16 to the subject.

18. A kit comprising:
i) at least a first composition comprising a RNA encoding PSA, wherein the RNA is an mRNA comprising a Prostate-Specific Antigen (PSA) polypeptide coding sequence at least 90% identical to an RNA encoded by the sequence of SEQ ID NO: 3, wherein the polypeptide coding sequence encodes the PSA polypeptide sequence encoded by the sequence of SEQ ID NO: 3; and
ii) at least a second composition comprising a RNA encoding a polypeptide selected from the group consisting of Prostate-Specific Membrane Antigen (PSMA), Prostate Stem Cell Antigen (PSCA), and Six Transmembrane Epithelial Antigen of the Prostate (STEAP).

Assignees

• CureVac SE

Inventors

• Probst Jochen
• Hoerr Ingmar
• Lander Thomas

Classifications

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• A61K39/001194

  Prostate specific antigen [PSA] · CPC title

• A61K39/001193 Primary

  Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR · CPC title

• A61K39/001195

  Prostate specific membrane antigen [PSMA] · CPC title

• A61K39/39

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title